Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
GLP-1 Receptor Activation This is the same pathway used by Semaglutide (Ozempic, Wegovy): Suppresses appetite via hypothalamic signaling Delays gastric emptying , prolonging fullness Improves insulin secretion and glucose control Lowers postprandial glucose and insulin resistance GIP Receptor Activation Shared with Tirzepatide, GIP provides several synergistic effects: Enhances insulin release in response to meals May reduce GI side effects (like nausea) seen with GLP-1s alone Potentially improves lipid metabolism and adipose tissue response Glucagon Receptor Activation This is where Retatrutide takes a leap beyond dual agonists: Increases energy expenditure and fat oxidation Mobilizes stored fat through hepatic lipolysis May preserve or enhance lean mass during weight loss Supports brown fat activation and thermogenesis The addition of glucagon receptor activation to GLP-1 and GIP may enhance fat oxidation and energy burn beyond whats seen with dual agonists. Coskun et al., Cell Metabolism Together, these pathways work synergistically: GLP-1 blunts hunger , GIP improves insulin dynamics , and glucagon turns up fat-burning efficiency
Boxes of the diabetes drug Ozempic rest on a pharmacy counter in Los Angeles
Most insurance plans do not cover these medications for weight loss as its claimed to be a vanity. I personally believe that if someone is overweight and wishes to seek help via medication, they should absolutely have access to them, Clasen said
Many people taking Wegovy (semaglutide) for weight management experience gastrointestinal symptoms such as nausea, diarrhoea, or indigestion
